Structural considerations of plasmic degradation of fibrinogen. 1974

V J Marder, and A Z Budzynski

UI MeSH Term Description Entries
D005338 Fibrin Fibrinogen Degradation Products Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis. Antithrombin VI,Fibrin Degradation Product,Fibrin Degradation Products,Fibrin Fibrinogen Split Products,Degradation Product, Fibrin,Degradation Products, Fibrin,Product, Fibrin Degradation
D005340 Fibrinogen Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products. Coagulation Factor I,Factor I,Blood Coagulation Factor I,gamma-Fibrinogen,Factor I, Coagulation,gamma Fibrinogen
D005341 Fibrinolysin A product of the lysis of plasminogen (profibrinolysin) by PLASMINOGEN activators. It is composed of two polypeptide chains, light (B) and heavy (A), with a molecular weight of 75,000. It is the major proteolytic enzyme involved in blood clot retraction or the lysis of fibrin and quickly inactivated by antiplasmins. Plasmin,Fibrogammin,Glu-Plasmin,Protease F,Thrombolysin,Glu Plasmin
D005342 Fibrinolysis The natural enzymatic dissolution of FIBRIN. Fibrinolyses
D005344 Fibrinopeptide A Two small peptide chains removed from the N-terminal segment of the alpha chains of fibrinogen by the action of thrombin during the blood coagulation process. Each peptide chain contains 18 amino acid residues. In vivo, fibrinopeptide A is used as a marker to determine the rate of conversion of fibrinogen to fibrin by thrombin. Fibrinopeptides A
D005345 Fibrinopeptide B Two small peptide chains removed from the N-terminal segment of the beta chains of fibrinogen by the action of thrombin. Each peptide chain contains 20 amino acid residues. The removal of fibrinopeptides B is not required for coagulation. Fibrinopeptides B
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D066298 In Vitro Techniques Methods to study reactions or processes taking place in an artificial environment outside the living organism. In Vitro Test,In Vitro Testing,In Vitro Tests,In Vitro as Topic,In Vitro,In Vitro Technique,In Vitro Testings,Technique, In Vitro,Techniques, In Vitro,Test, In Vitro,Testing, In Vitro,Testings, In Vitro,Tests, In Vitro,Vitro Testing, In

Related Publications

V J Marder, and A Z Budzynski
January 1971, Scandinavian journal of haematology. Supplementum,
V J Marder, and A Z Budzynski
May 1972, Biochimica et biophysica acta,
V J Marder, and A Z Budzynski
May 1973, Biochimica et biophysica acta,
V J Marder, and A Z Budzynski
December 1983, The Journal of laboratory and clinical medicine,
V J Marder, and A Z Budzynski
February 1977, Thrombosis and haemostasis,
V J Marder, and A Z Budzynski
June 2003, Journal of thrombosis and haemostasis : JTH,
V J Marder, and A Z Budzynski
July 1975, Biochimica et biophysica acta,
V J Marder, and A Z Budzynski
December 1975, Thrombosis et diathesis haemorrhagica,
V J Marder, and A Z Budzynski
August 1975, Biochimica et biophysica acta,
V J Marder, and A Z Budzynski
April 1978, Thrombosis research,
Copied contents to your clipboard!